{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:57Z","timestamp":1790876697154,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2314-B-075A-023"],"award-info":[{"award-number":["NSTC 114-2314-B-075A-023"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1152201B"],"award-info":[{"award-number":["TCVGH-1152201B"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1142201A"],"award-info":[{"award-number":["TCVGH-1142201A"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["CE24430C-1"],"award-info":[{"award-number":["CE24430C-1"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xops.2026.101245","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:45:47Z","timestamp":1779493547000},"page":"101245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4620-1755","authenticated-orcid":false,"given":"Ssu-Yu","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsiang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jing","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Jong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-0900","authenticated-orcid":false,"given":"Chien-Chih","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xops.2026.101245_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"10295","key":"10.1016\/j.xops.2026.101245_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.xops.2026.101245_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.xops.2026.101245_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2337\/cd22-0060","article-title":"Tirzepatide: a novel glucose-dependent insulinotropic Polypeptide\/Glucagon-Like peptide 1 receptor agonist for the treatment of type 2 diabetes: the first twincretin","volume":"41","author":"Fanshier","year":"2023","journal-title":"Clin Diabetes"},{"issue":"10","key":"10.1016\/j.xops.2026.101245_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.40890","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.xops.2026.101245_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.xops.2026.101245_bib7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.xops.2026.101245_bib8","article-title":"An observational Study of cardiovascular outcomes of tirzepatide vs glucagon-like Peptide-1 receptor agonists","volume":"4","author":"Dani","year":"2025","journal-title":"JACC: Adv"},{"issue":"7","key":"10.1016\/j.xops.2026.101245_bib9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.ophtha.2010.11.022","article-title":"The relationship between components of metabolic syndrome and open-angle glaucoma","volume":"118","author":"Newman-Casey","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.xops.2026.101245_bib10","article-title":"Role of excessive weight in intraocular pressure: a systematic review and meta-analysis","volume":"8","author":"Noro","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"issue":"2","key":"10.1016\/j.xops.2026.101245_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.xops.2026.101245_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2024.08.023","article-title":"Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes","volume":"132","author":"Muayad","year":"2025","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.xops.2026.101245_bib13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between Glucagon-like Peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.xops.2026.101245_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100827","article-title":"Association of dipeptidyl Peptidase-4 inhibitors with glaucoma risk in patients with type 2 diabetes: a nationwide cohort Study","volume":"5","author":"Lu","year":"2025","journal-title":"Ophthalmol Sci"},{"issue":"2","key":"10.1016\/j.xops.2026.101245_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"5","key":"10.1016\/j.xops.2026.101245_bib16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00228-025-03823-9","article-title":"Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region-a register-based cross-sectional study","volume":"81","author":"Fors","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xops.2026.101245_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ajo.2024.10.029","article-title":"Sodium-Glucose cotransporter 2 inhibitors for the primary prevention of glaucoma in patients with type 2 diabetes: a target trial emulation","volume":"271","author":"Eng","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101245_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ajo.2024.12.024","article-title":"GLP-1 receptor agonists use and incidence of glaucoma: a systematic review and meta-analysis","volume":"271","author":"Amaral","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"10300","key":"10.1016\/j.xops.2026.101245_bib19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.xops.2026.101245_bib20","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del","year":"2021","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.xops.2026.101245_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.xops.2026.101245_bib22","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1111\/dom.15934","article-title":"Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus","volume":"26","author":"Kelly","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.xops.2026.101245_bib23","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1111\/dom.16372","article-title":"Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States","volume":"27","author":"Mody","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.xops.2026.101245_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1016\/j.xops.2026.101245_bib25","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.jacc.2025.03.516","article-title":"Effects of Tirzepatide in Type 2 diabetes","volume":"85","author":"Aminorroaya","year":"2025","journal-title":"JACC"},{"issue":"10","key":"10.1016\/j.xops.2026.101245_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.xops.2026.101245_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1076\/ceyr.25.6.381.14238","article-title":"Upregulation of glucose-dependent insulinotropic polypeptide and its receptor in the retina of streptozotocin-induced diabetic rats","volume":"25","author":"Cho","year":"2002","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.xops.2026.101245_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00417-006-0282-x","article-title":"Glucagon-related peptides in the mouse retina and the effects of deprivation of form vision","volume":"245","author":"Mathis","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.xops.2026.101245_bib29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2026.101245_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/975032","article-title":"Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1)","volume":"2013","author":"Puddu","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.xops.2026.101245_bib31","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"9","key":"10.1016\/j.xops.2026.101245_bib32","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.xops.2026.101245_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.xops.2026.101245_bib34","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526001831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526001831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:16:17Z","timestamp":1785892577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666914526001831"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101245","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101245"}}